EUVIMEDEUVIMED entdecken
Open Access

Clinical, pathologic, and molecular features of amphicrine prostate cancer

Laura S Graham iD, Michael C Haffner iD, Erolcan Sayar iD, Agnes Gawne, Michael T Schweizer iD, Colin C Pritchard, Ilsa Coleman, Peter S Nelson, Evan Y Yu

The Prostate · 2023

DOI: 10.1002/pros.24497 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2023. Verfasst von Laura S Graham und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology , University of Colorado, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Carcinoma, Neuroendocrine, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, U.S. Department of Defense, Doris Duke Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Amphicrine prostate carcinoma (AMPC) is a poorly defined subset of prostate cancer in which cells co‐express luminal prostate epithelial and neuroendocrine markers. The optimal treatment strategy is unknown. We sought to further characterize the clinical, histomorphologic, and molecular characteristics of AMPC and to identify areas of potential future treatment investigations.

Methods

We retrospectively identified 17 cases of AMPC at a single institution, defined as synaptophysin expression in >70% of cells and co‐expression of androgen receptor (AR) signaling markers (either AR, PSA, or NKX3.1) in >50% of cells. Clinical and histologic features of AMPC cases as well as response to treatment and clinical outcomes were described.

Results

Five AMPC cases arose de novo in the absence of prior systemic treatment and behaved distinctly from cases that were treatment‐emergent. In these de novo cases, despite expression of neuroendocrine markers, prognosis appeared more favorable than high‐grade neuroendocrine carcinoma, with two (40%) patients with de novo metastatic disease, universal response to androgen deprivation therapy, and no deaths at a median follow‐up of 12.3 months. Treatment‐emergent AMPC arose a median of 41.1 months after androgen deprivation therapy initiation and was associated with poor response to therapy.

Conclusions

We show that amphicrine prostate cancer is a unique entity and differs in clinical and molecular features from high‐grade neuroendocrine carcinomas of the prostate. Our study highlights the need to recognize AMPC as a unique molecularly defined subgroup of prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCarcinoma, NeuroendocrineProstatic Neoplasms, Castration-ResistantMaleHumansRetrospective StudiesAndrogen AntagonistsAndrogensProstate

Stichwörter der Autor:innen

amphicrine prostate cancercastration resistant prostate cancerneuroendocrinesynaptophysin

Substanzen

Androgen AntagonistsAndrogens

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Medical Oncology , University of Colorado, Aurora, Colorado, USA.
  • Divisions of Human Biology and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Internal Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Lab Medicine, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Laura S Graham, Michael C Haffner, Erolcan Sayar, Michael T Schweizer

Förderung

  • NCI NIH HHS
  • U.S. Department of Defense
  • Doris Duke Charitable Foundation
  • National Institutes of Health

Zitieren

APA

Graham, L. S., Haffner, M. C., Sayar, E., Gawne, A., Schweizer, M. T., Pritchard, C. C., Coleman, I., Nelson, P. S., & Yu, E. Y. (2023). Clinical, pathologic, and molecular features of amphicrine prostate cancer. The Prostate. https://doi.org/10.1002/pros.24497

Vancouver

Graham LS, Haffner MC, Sayar E, Gawne A, Schweizer MT, Pritchard CC, et al. Clinical, pathologic, and molecular features of amphicrine prostate cancer. The Prostate. 2023. doi:10.1002/pros.24497

BibTeX
@article{Graham2023,
  author = {Graham, Laura S and Haffner, Michael C and Sayar, Erolcan and Gawne, Agnes and Schweizer, Michael T and Pritchard, Colin C and Coleman, Ilsa and Nelson, Peter S and Yu, Evan Y},
  title = {Clinical, pathologic, and molecular features of amphicrine prostate cancer},
  journal = {The Prostate},
  year = {2023},
  doi = {10.1002/pros.24497}
}
Kostenlos starten →